Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Apixaban is the active ingredient of these drugs:
Ecuador Estonia Lithuania Poland Romania
Estonia Romania
Turkey
Estonia Romania
Ecuador
Australia Austria Brazil Canada Cyprus
Turkey
Tunisia
Ecuador
Ecuador
Turkey
Poland
Turkey
South Africa